Literature DB >> 34086923

Prevalence of SARS-CoV-2 antibodies in New York City adults, June-October, 2020: a population-based survey.

Jannae C Parrott1, Ariana N Maleki1, Valerie E Vassor1, Sukhminder Osahan1, Yusyin Hsin1, Michael Sanderson1, Steven Fernandez1, Amber Levanon Seligson1, Scott Hughes1, Jing Wu1, Andrea K DeVito1, Stephen P LaVoie1, Jennifer L Rakeman1, L Hannah Gould1, Karen A Alroy1,2.   

Abstract

BACKGROUND: Serosurveys are important to ascertain burden of infection. Prior SARS-CoV-2 serosurveys in New York City (NYC) have used nonrandom samples. During June-October 2020, the NYC Health Department conducted a population-based survey to estimate SARS-CoV-2 antibody prevalence in NYC adults.
METHODS: Participants were recruited from the NYC 2020 Community Health Survey. We estimated citywide and stratified antibody prevalence using a hybrid design: serum tested at the NYC Health Department using the DiaSorin LIAISON ® SARS-CoV-2 S1/S2 IgG assay and self-reported antibody test results were used together. Prevalence was estimated using univariate frequencies and 95% confidence intervals (CI), accounting for complex survey design. Two-sided P-values ≤0.05 were statistically significant.
RESULTS: There were 1074 respondents overall; 497 provided blood and 577 provided only a self-reported antibody test result. Weighted prevalence was 24.3% overall (95% CI: 20.7-28.3). Latino (30.7%, 95% CI: 24.1-38.2, p<0.01) and Black (30.7%, 95% CI: 21.9-41.2, p=0.02) respondents had a higher weighted prevalence compared with White respondents (17.4%, 95% CI: 12.5-23.7).
CONCLUSIONS: By October 2020, nearly 1 in 3 Black and 1 in 3 Latino NYC adults had SARS-CoV-2 antibodies, highlighting unequal impacts of the COVID-19 pandemic on Black and Latino adults in NYC. Published by Oxford University Press for the Infectious Diseases Society of America 2021.

Entities:  

Keywords:  New York City; SARS-CoV-2; antibody prevalence; population-based; seroprevalence

Year:  2021        PMID: 34086923     DOI: 10.1093/infdis/jiab296

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.

Authors:  Kiersten J Kugeler; Laura J Podewils; Nisha B Alden; Tori L Burket; Breanna Kawasaki; Brad J Biggerstaff; Holly M Biggs; Rachael Zacks; Monique A Foster; Travis Lim; Emily McDonald; Jacqueline E Tate; Rachel K Herlihy; Jan Drobeniuc; Margaret M Cortese
Journal:  Public Health Rep       Date:  2021-11-09       Impact factor: 2.792

2.  Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020-March 2021.

Authors:  Jannae C Parrott; Ariana Maleki Annibale; Sukhminder Osahan; Karen Alroy; Jo-Anne Caton; Claudia Chernov; Sarah Dumas; Randal C Fowler; Gabriella Hermosi; Yusyin Hsin; Sharon Perlman; Jing Wu; Scott Hughes; L Hannah Gould; Anne Schuster
Journal:  Epidemiol Infect       Date:  2022-05-18       Impact factor: 4.434

3.  Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications.

Authors:  Andrew T Levin; Nana Owusu-Boaitey; Sierra Pugh; Bailey K Fosdick; Anthony B Zwi; Anup Malani; Satej Soman; Lonni Besançon; Ilya Kashnitsky; Sachin Ganesh; Aloysius McLaughlin; Gayeong Song; Rine Uhm; Daniel Herrera-Esposito; Gustavo de Los Campos; Ana Carolina Pecanha Peçanha Antonio; Enyew Birru Tadese; Gideon Meyerowitz-Katz
Journal:  BMJ Glob Health       Date:  2022-05

4.  Adapting Survey Data Collection to Respond to the COVID-19 Pandemic: Experiences From a Local Health Department.

Authors:  Amber Levanon Seligson; Karen A Alroy; Michael Sanderson; Ariana N Maleki; Steven Fernandez; April Aviles; Sarah E Dumas; Sharon E Perlman; Kathryn Peebles; Christina C Norman; R Charon Gwynn; L Hannah Gould
Journal:  Am J Public Health       Date:  2021-12       Impact factor: 9.308

5.  Socioeconomic Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 Serological Testing and Positivity in New York City.

Authors:  Wil Lieberman-Cribbin; Marta Galanti; Jeffrey Shaman
Journal:  Open Forum Infect Dis       Date:  2021-10-17       Impact factor: 3.835

6.  Severe respiratory viral infections in children with history of asymptomatic or mild COVID-19.

Authors:  Nooralam Rai; Joseph A Cornett; Philip Zachariah; Lynne Quittell; Stephanie Lovinsky-Desir
Journal:  Pediatr Pulmonol       Date:  2021-11-15

7.  Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020-May 2021.

Authors:  Alexia Couture; B Casey Lyons; Megha L Mehrotra; Lynn Sosa; Ngozi Ezike; Farah S Ahmed; Catherine M Brown; Stephanie Yendell; Ihsan A Azzam; Božena J Katić; Anna Cope; Kristen Dickerson; Jolianne Stone; L Brannon Traxler; John R Dunn; Lora B Davis; Carrie Reed; Kristie E N Clarke; Brendan Flannery; Myrna D Charles
Journal:  Open Forum Infect Dis       Date:  2022-01-30       Impact factor: 3.835

8.  Missing science: A scoping study of COVID-19 epidemiological data in the United States.

Authors:  Rajiv Bhatia; Isabella Sledge; Stefan Baral
Journal:  PLoS One       Date:  2022-10-12       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.